Vikas K. Goel

Bristol-Myers Squibb (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Magda Bahcall

Dana-Farber Cancer Institute

Danielle Haradon

Dana-Farber Cancer Institute

Simon Baldacci

Harvard University

Nishant Gandhi

Caris Life Sciences (United States)

C. Patrick

Penn State Milton S. Hershey Medical Center

Stephen V. Liu

Georgetown University Medical Center

Andrew Elliott

Caris Life Sciences (United States)

Federica Pecci

University of Parma

Balázs Halmos

Montefiore Medical Center

Rebecca S. Heist

Massachusetts General Hospital

Cooperative Institutions

Dana-Farber Cancer Institute

Harvard University

Brigham and Women's Hospital

Massachusetts General Hospital

Memorial Sloan Kettering Cancer Center

Dana-Farber Brigham Cancer Center

Center for Orthopaedics

Center for Neuro-Oncology

Caris Life Sciences (United States)

Boston University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Figure 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Comparison of missense MET TKD defined as “probably pathogenic” and “probably benign” according to three in silico tools. Comparison of (A) secondary structure features, (B) relative solvent accessible surface area (RSA), and (C) mutant amino acid properties of missense MET TKD mutations of unknown biological function according to OncoKB. Mutations were defined as “probably pathogenic” for likely pathogenicity across all three tools and as “probably benign” for likely benign across all three scores. OR: odds ratio; 95% CI: 95% confidence interval.

10.1158/2159-8290.26466980.v1

Cite

Citations (0)

Supplementary Figure 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Prevalence of MET TKD mutation in various cancer types according to OncoKB status in each dataset in cohort #1.

Protein kinase domain

10.1158/2159-8290.26466974.v1

Cite

Citations (0)

Supplementary Table 25 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

TCGA PanCancer Atlas Studies included in cohort #1 downloaded from cBioPortal.

Protein kinase domain

10.1158/2159-8290.26466860

Cite

Citations (0)

Supplementary Table 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Clinicopathologic and genomic characteristics of 171 cases of cancers other than NSCLC harboring oncogenic / likely oncogenic MET TKD mutations in cohort #2.

Protein kinase domain

10.1158/2159-8290.26466878.v1

Cite

Citations (0)

Supplementary Table 24 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Single trajectory generalized Born and surface area solvation (MM/GBSA) calculated free energy of ATP binding into the orthosteric pocket.

10.1158/2159-8290.26466866

Cite

Citations (0)

Supplementary Table 4 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohort #1

Protein kinase domain

10.1158/2159-8290.26466848.v1

Cite

Citations (0)

Supplementary Table 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Frequency of MET tyrosine kinase domain (TKD) mutations in cohort #2 according to amino acid residue, out of a total of 2,559 MET TKD mutations.

Protein kinase domain

10.1158/2159-8290.26466854

Cite

Citations (0)

Supplementary Table 26 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Mutagenic primers used for mutagenesis.

Protein kinase domain

10.1158/2159-8290.26466857

Cite

Citations (0)

Supplementary Figure 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Equilibration of interactions that drives ATP affinity in the presence MET R1170Q mutant. (A) Representative structure of ATP bound MET R1170Q with the regions of interest highlighted [hinge site (green), and mutation site (blue)]. (B) Mutation at position 1170 facilitates the formation of a hydrogen bonding network. (C) Interatomic distances for non solvent mediated hydrogen bonding.

Protein kinase domain

10.1158/2159-8290.26466983.v1

Cite

Citations (0)

Supplementary Table 19 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci Seshiru Nakazawa Biagio Ricciuti Guilherme Harada Jessica Lee

Detailed clinicopathologic and genomic characteristics related to renal cell cancer cases in cohort #1.

Protein kinase domain

10.1158/2159-8290.26466884.v1

Cite

Citations (0)